ClinicalTrials.gg
RecruitingNCT06979037Updated May 18, 2025

Genetic Markers of Diabetic Ulcers and Personalized Treatment Targets Research

An observational study in Diabetic Ulcers, sponsored by The First Affiliated Hospital of University of South China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by The First Affiliated Hospital of University of South China · Observational

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
712
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial involves collecting peripheral blood, ulcer tissue, and fecal samples from diabetic ulcer patients for bioinformatics analysis to screen genetic markers significantly associated with ulcer risk and healing differences. Furthermore, multi-omics data will be integrated to establish a diabetic ulcer risk prediction model. Based on key single nucleotide polymorphisms and their regulatory pathways, potential new drug targets for promoting healing will be explored, providing a genetic basis for personalized treatment.

02

Conditions studied

  • Diabetic Ulcers

Browse trials for

Keywords

  • Diabetic Ulcers
03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 62 are open to participants now.

This study's planned enrollment of 712 is above the median of 100 across 55 observational studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

The First Affiliated Hospital of University of South China is the lead sponsor of 13 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of diabetic ulcer patients who visit the The First Affiliated Hospital of University of South China during the trial period and meet the inclusion/exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Subjects who voluntarily participate in this clinical study and sign ;
    1. Patients with type 2 diabetes and diabetic ulcers;
    1. Disease duration ≥ 10 years or age ≥ 55 years at enrollment;
    1. Inpatient or outpatient who can be monitored by the same investigating team throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

    1. Severe vascular occlusion or impairment;
    1. Patients with congenital heart disease, aortic dissection, or other severe cardiovascular diseases;
    1. Patients with ulcers caused by factors other than diabetes;
    1. Patients with severe liver and kidney dysfunction or serious neurological impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
712 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Ulcer Healing Time

    Time frame: Three years

Secondary outcomes

  1. Absolute Change in Ulcer Area

    Absolute change in ulcer area over three years in cm2

    Time frame: Three years

  2. Number of Amputation Events

    Time frame: Three years

  3. Ulcer Recurrence

    Number of diabetic foot ulcers with recurrence at three years

    Time frame: Three years

  4. Time to Complete Wound Closure

    Time to 100% wound closure utilizing Cox proportional hazards model, a statistical measure of difference of time to event (healing). The analysis will consider covariates that might influence the outcome in the trial.

    Time frame: Three years or wound closure

  5. Number of Foot Infections

    Time frame: Three years

  6. Quality of Life Assessment

    The Cardiff Wound Impact Schedule questionnaire to measure quality of life. Measure of well-being items from each scale are summated, physical symptoms, everyday living and social life. The items are rated for the extent of the experience and each item is given a number value. This allows the patients to weight the items included in the scale. The well-being scale is scored on a 5-point Likert scale, with response options from 'strongly agree' to 'strongly disagree'. All three scales are then transformed onto a minimum = 0 up to a maximum = 100, where a low score indicates worse, and a high score indicates better feeling of well-being.

    Time frame: Three years

  7. Length of Stay

    Time frame: Three years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979037
Lead sponsor
The First Affiliated Hospital of University of South China
Responsible party
Sponsor
First posted
May 18, 2025
Start date
May 16, 2024
Primary completion
May 16, 2027 (estimated)
Completion
May 16, 2027 (estimated)
Last update
May 18, 2025

Study contacts

Jiecan Zhou, Prof.
Contact
zhoujiecan@fsyy.usc.edu.cn
+86-734-8279018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion